Daoxi Lei

Prof. Dr. Daoxi Lei

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2023 in Journal of Environmental Science and Health, Part B
Verified
Journal Article
Closed access
YYYuepei Yan
Yuepei Yan
SLShuang Liang
Shuang Liang
TZTao Zhang
Tao Zhang
CDChengchen Deng
Chengchen Deng
HLHuili Li
Huili Li
GWGuixue Wang
Guixue Wang
Isopyrazam (IPZ) is one of the broad-spectrum succinate dehydrogenase inhibitor fungicides (SDHIs). Although the potential bio-toxicity of SDHIs has been reported hourly, the specific effects focused on the cardiovascular system have remained unclear and piecemeal. Thus, we chose IPZ as a representative to observe the cardiovascular toxicity of SDHIs in zebrafish. Two types of transgenic zebrafish, Tg (cmlc2:GFP) and Tg (flk1:GFP) were used in this study. Healthy embryos at 6 hpf were exposed to IPZ solutions. The statistical data including survival rate, hatching rate, malformed rate, and morphological and functional parameters of the cardiovascular system at 48 hpf and 72 hpf demonstrated that IPZ could cause abnormalities and cardiovascular defects such as spinal curvature, dysmotility, pericardial edema, pericardial hemorrhage, and slowed heart rate, etc. At the same time, the activity of enzymes related to oxidative stress was altered with IPZ. Our results revealed that IPZ-induced cardiovascular toxicity and oxidative stress might be one of the underlying toxic mechanisms.

4 September 2026 in Medicine
Verified
Journal Article
Open access
KCKaiyao Chi
Kaiyao Chi
XXXiaoyang Xie
Xiaoyang Xie
TGTong Guo
Tong Guo
DLDaoxi Lei
Daoxi Lei
HLHuili Li
Huili Li
Rationale: Purtscher-like retinopathy is an extremely rare, vision-threatening microvascular complication of systemic lupus erythematosus (SLE). To date, there is no standardized, unified treatment guideline for this condition worldwide, and conventional interventions including systemic glucocorticoids, immunosuppressants, and anti- vascular endothelial growth factor therapy often yield unsatisfactory visual outcomes. Additionally, the early ocular manifestations of SLE are easily overlooked due to atypical systemic symptoms, leading to delayed diagnosis and irreversible visual impairment. Patient concerns: A 24-year-old female developed blurred vision after coronavirus disease 2019 infection, which was initially neglected. She subsequently presented with persistent fever, lymphadenopathy, recurrent seizures and altered consciousness, and was diagnosed with SLE complicated by neuropsychiatric lupus. Her visual loss progressively aggravated during systemic treatment. Diagnoses: Systemic workup confirmed active SLE with neuropsychiatric involvement. Serial ophthalmic examinations revealed bilateral Purtscher-like retinopathy characterized by venous tortuosity, extensive cotton-wool spots, retinal hemorrhages, macular edema, diffuse capillary non-perfusion, and foveal arteriovenous anastomosis, with secondary right eye vitreous hemorrhage. Interventions: On the basis of standard SLE treatment with glucocorticoids and immunosuppressants, comprehensive interventions were implemented, including blood pressure optimization, anticoagulant discontinuation to mitigate bleeding risk, fractional panretinal photocoagulation for retinal ischemia, and adjunctive modified Ditan Decoction based on Traditional Chinese Medicine syndrome differentiation. Outcomes: During follow-up, blood pressure was gradually stabilized. Right eye vitreous hemorrhage resolved completely without recurrent bleeding. Retinal ischemia improved after photocoagulation, with partial regression of foveal arteriovenous anastomosis. Visual acuity improved modestly and remained stable at the final assessment. Lessons: Ocular microvascular lesions may precede systemic disease flares in SLE, underscoring the necessity of routine ophthalmologic screening for newly diagnosed patients, particularly those with neuropsychiatric involvement. Adjunctive Traditional Chinese Medicine therapy may offer incremental benefit for refractory Purtscher-like retinopathy, representing a complementary strategy that warrants further investigation.

28 September 2026 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
HLHuili Li
Huili Li
SPShengke Peng
Shengke Peng
DLDaoxi Lei
Daoxi Lei
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have revolutionized the treatment of type 2 diabetes and obesity, yet their ocular safety profile remains contested. The longer-acting semaglutide has been repeatedly linked to an increased risk of non-arteritic anterior ischemic optic neuropathy (NAION) and, in situations of rapid glycemic correction, to early deterioration of diabetic retinopathy, while shorter-acting drugs such as liraglutide and exenatide show much weaker signals. This review explores the pharmacological underpinnings of this difference by combining three lines of evidence: biased agonism and trafficking at the receptor level, cell-type-specific signaling microenvironments, and a recently proposed hemodynamic mechanism based on GLP-1RA-mediated changes in intracranial pressure. The ocular liabilities of GLP-1RAs may be influenced by a multifactorial interplay between ligand-dictated receptor occupancy profiles, cell-type-specific signaling milieu, and individual anatomical vulnerabilities. This model makes testable predictions and has implications for drug choice, risk stratified monitoring, and the development of future agonists with enhanced ocular safety. Key areas for future research include head-to-head comparisons of different GLP-1RAs' signaling in specific ocular cell types and the risk-benefit equation in non-diabetic individuals using these drugs for weight loss.